2020
DOI: 10.1590/0037-8682-0454-2019
|View full text |Cite
|
Sign up to set email alerts
|

Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports

Abstract: Introduction: Thalidomide is an anti-tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL). Because of its teratogenic potential it has to be used under proper supervision. Our critical analysis tries to look into the rationale with which it has been used by means of case reports on lepra reaction. Methods: We looked for the case reports between December 2005 to June 2019 in databases like Pubmed, Embase and other relevant resources… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 33 publications
(31 reference statements)
0
3
0
Order By: Relevance
“…It is a difficult condition to manage as patients require prolonged courses of high-dose prednisolone with risks of adverse effects (AEs), such as hypertension, diabetes or osteoporosis and steroid dependency along with immunosuppression. 1 Steroid sparing agents such as thalidomide, 2 clofazimine, minocycline, cyclosporine, pentoxifylline, azathioprine and methotrexate have been used with variable success rates.…”
mentioning
confidence: 99%
“…It is a difficult condition to manage as patients require prolonged courses of high-dose prednisolone with risks of adverse effects (AEs), such as hypertension, diabetes or osteoporosis and steroid dependency along with immunosuppression. 1 Steroid sparing agents such as thalidomide, 2 clofazimine, minocycline, cyclosporine, pentoxifylline, azathioprine and methotrexate have been used with variable success rates.…”
mentioning
confidence: 99%
“…When patients do not respond to either clofazimine or clofazimine and prednisolone, thalidomide is explored. Additionally, in the treatment of ENL, thalidomide should be administered in conjunction with steroids in a dosage range of 100 to 400 mg as a split dose in cases of neuritis [16]. Dapsone-induced hemolytic anemia, a frequent adverse drug reaction in leprosy patients taking daily dapsone dose, is often addressed by discontinuing the drug; however, in those cases, ofloxacin or minocycline may be given to patients as an alternate therapy [17].…”
Section: Discussionmentioning
confidence: 99%
“…Several systemic and dermatologic conditions may potentially be treated with thalidomide (Table 1) [4][5][6][7][8][9][10][11][12][13][14][15][16].…”
Section: Discussionmentioning
confidence: 99%